Can We Do Better with a New Chemotherapy for Squamous Cell NSCLC?

Can We Do Better with a New Chemotherapy for Squamous Cell NSCLC?

From: GRACEcast
0 0 5 years ago
A Japanese study of squamous cell carcinoma showed value in nedaplatin vs cisplatin/Taxotere (docetaxel). But with differences in how Asian versus Caucasian patients metabolize chemotherapy, can we presume this benefit would exist for everyone?

Find us on Facebook